Piclamilast is a type 4 phosphodiesterase (PDE4) inhibitor with equal affinity for the high-affinity rolipram binding site (HARBS) and low-affinity rolipram binding site (LARBS ICI 63,197, and Ro 20-1724 were better described by a two-site model, while the competition curves for piclamilast, cilomilast, roflumilast, and CDP 840 were adequately described by a one-site model. Inhibitors of other PDE families were much less potent. The inhibition of [ 3 H]piclamilast was further tested in the presence of 1 M rolipram to isolate the LARBS. Under this condition, the competition curves for all the inhibitors were adequately described by a one-site model, with K i values close to that for the LARBS. The results indicated that [ 3 H]piclamilast is a useful tool to directly study inhibitor interaction with the HARBS and the LARBS in rat brain.
PDE4 inhibitors tested were potent competitors for [
3 H]piclamilast binding; the competition curves for rolipram, desmethylpiclamilast, ICI 63, 197 , and Ro 20-1724 were better described by a two-site model, while the competition curves for piclamilast, cilomilast, roflumilast, and CDP 840 were adequately described by a one-site model. Inhibitors of other PDE families were much less potent. The inhibition of [ 3 H]piclamilast was further tested in the presence of 1 M rolipram to isolate the LARBS. Under this condition, the competition curves for all the inhibitors were adequately described by a one-site model, with K i values close to that for the LARBS. The results indicated that [ 3 H]piclamilast is a useful tool to directly study inhibitor interaction with the HARBS and the LARBS in rat brain.
Cyclic nucleotide phosphodiesterases (PDEs) hydrolyze the second messengers cyclic AMP and cyclic GMP. The mammalian PDEs have been classified into 11 families (Manganiello et al., 1995; Conti and Jin, 1999; Soderling and Beavo, 2000; Francis et al., 2001) . The PDE4 family, encoded by four genes (PDE4A-D), is characterized by its low K m value for cAMP and its sensitivity to inhibition by rolipram (Beavo et al., 1994 (Beavo et al., , 1995 Bolger, 1994) . PDE4 inhibitors show promising pharmacological effects in a variety of disease models, particularly asthma and depression (Torphy and Undem, 1991; O'Donnell, 1993; Giembycz, 1996; O'Donnell and Frith, 1999) . However, central nervous system and gastrointestinal side effects remain a problem, limiting clinical development. It has been speculated that some of the side effects may be mediated through inhibitor interaction with the high-affinity rolipram binding site (HARBS) on PDE4 (Barnette et al., 1995; Duplantier et al., 1996) ; rolipram and a number of other PDE4 inhibitors have been shown to bind with low nanomolar affinity to this site (Schneider et al., 1986; Torphy et al., 1992; Jacobitz et al., 1996) .
In addition to binding to the HARBS, PDE4 inhibitors also bind to a low-affinity state, termed the low-affinity rolipram binding site (LARBS). It should be noted that the terminology of HARBS and LARBS refers specifically to rolipram binding. Some inhibitors bind with high affinity to both the HARBS and the LARBS (e.g., piclamilast). A study using truncated PDE4A mutants indicated that inhibitor binding to both the HARBS and the LARBS is to the catalytic site (Jacobitz et al., 1996) . Binding to the HARBS, but not the LARBS, depends on the presence of the N-terminal region. Although their exact natures are still unclear, it appears the HARBS and the LARBS are more accurately described as two distinct binding affinity states, rather than separate sites (Schneider et al., 1986; Torphy et al., 1992; Souness and Scott, 1993; Jacobitz et al., 1996) .
Interestingly, the rank-order potency of a variety of compounds for inhibiting PDE4 catalytic activity differs from their rank-order potency for competing with [ 3 H]rolipram binding to the HARBS (Torphy et al., 1992; Baures et al., 1993) . Although the function of the HARBS is unknown, the potency of PDE4 inhibitors to produce certain effects, such as emesis and increased gastric acid secretion, correlates with their ability to displace [ 3 H]rolipram from this site. Other effects are more related to their ability to inhibit PDE4 catalytic activity in a cell-free system, which provides an index of inhibitor interaction with the LARBS (Harris et al., 1989; Barnette et al., 1995 Barnette et al., , 1996 Duplantier et al., 1996; Souness et al., 1996) . These findings suggest that the pharmacological effects that result from the interaction of inhibitors with the HARBS and the LARBS are distinct. This is particularly evident when one compares the effects of piclamilast (RP 73, 401) and rolipram. Piclamilast is about 1000-fold more potent than rolipram for inhibiting guinea pig smooth muscle PDE4, but only about 4-fold more potent for inhibiting methacholine-induced contraction of guinea pig trachealis muscle or enhancing isoproterenol-stimulated cyclic AMP formation in guinea pig eosinophils (Ashton et al., 1994; Souness et al., 1995) .
Piclamilast is a selective and potent PDE4 inhibitor (Karlsson et al., 1993; Ashton et al., 1994) . PDE4 isolated from various cell types is inhibited by piclamilast with a K i value of about 1 nM (Ashton et al., 1994) . Piclamilast displays similar potency for inhibition of PDE4 regardless of the source and the procedure used to prepare the enzyme; rolipram potency, by contrast, is dependent on such factors (Schwabe et al., 1976; Fredholm et al., 1979; Ruckstuhl and Landry, 1981; Lugnier et al., 1983; Davis, 1984; Schneider et al., 1986) . Piclamilast does not exhibit differential affinity for the HARBS and the LARBS; it binds with low nanomolar affinity to both states of PDE4 (Souness et al., 1995) . Rolipram, by contrast, exhibits approximately 500-fold greater affinity for the HARBS relative to the LARBS (Schneider et al., 1986; Torphy et al., 1992; Jacobitz et al., 1996) 
Materials and Methods
Animals. Male Sprague-Dawley rats (Harlan, Indianapolis, IN) were housed in a temperature-(22-24°C) and light-(on 6:00 AM-6:00 PM) controlled room and were allowed free access to food pellets and water. Their use in studies reported in this article have been carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health and have been approved by the Animal Care and Use Committee of the University of Tennessee Health Science Center.
Radioligand Binding Assays. Rats were killed by decapitation. Brain regions (cerebral cortex, hippocampus, amygdala, hypothalamus, neostriatum, cerebellum, and brain stem) and peripheral tissues (heart, liver, and skeletal muscle) were dissected on ice and homogenized in binding buffer (50 mM Tris-HCl, 5 mM MgCl 2 , pH 7.5) using a Polytron homogenizer (Brinkman Instruments, Westbury, NY). Separation of supernatant and particulate fractions was achieved by centrifugation at 15,000g for 15 min; the pellet then was resuspended in binding buffer.
[ Statistical Analysis. Data were analyzed by nonlinear regression to determine whether inhibitor binding to PDE4 was better described by an interaction with one or two binding sites (Draper and Smith, 1966; O'Donnell et al., 1984) . Binding to a single site was assumed unless the data were better described by a two-site binding equation. This was indicated when the residual sum of square was reduced significantly (F ratio, p Ͻ 0.01).
B max and K d values were determined for saturation experiments. EC 50 values were determined for competition experiments; K i values were calculated from EC 50 values using the method of Cheng and Prusoff (1973) . All values are expressed as mean Ϯ S.E.M. from at least three independent experiments carried out in duplicate. Distribution of High-and Low-Affinity Sites.
[ 3 H]Piclamilast binding to preparations of various regions of brain and peripheral tissues was determined in the presence of different concentrations of rolipram. Data were analyzed by nonlinear regression to assess potential one-or two-site binding. Rolipram inhibition using preparations of the brain regions was better described by a two-site model, while the inhibition using the peripheral tissue preparations was adequately described by a one-site model ( Fig. 4; Table 2 ). In all the brain regions examined, approximately 60% of the total specific binding was to the high-affinity binding site; this was quite consistent across the different regions as well as for homogenate, membrane, and cytosolic preparations. Highaffinity binding was not detected in peripheral tissues ( Fig. 4 ; Table 2 ). The affinity values for the binding of rolipram to the low-affinity binding site were consistent for all the brain regions and the peripheral tissues, except for liver, for which an almost 100-fold lower affinity was observed. (Fig. 5) , the competition curves for rolipram, desmethylpiclamilast, ICI 63,197, Ro 20-1724, and cilomilast were better described by a two-site model; the competition curves for piclamilast, roflumilast, and CDP 840 were adequately described by a one-site model. For those inhibitors that bound to two sites, the K i values for the high-affinity interaction were all in the nanomolar range, while the K i values for low-affinity interaction were all in the low micromolar range.
All the curves for inhibition of [ 3 H]rolipram binding by PDE4 inhibitors were adequately described by a one-site model, with K i values in the low-to-mid-nanomolar range (Fig. 6) (Fig. 7) . The competition curves under this condition all were consistent with a one-site model.
Some non-PDE4 inhibitors were tested against both (Table 3) . Milrinone, trequinsin, and papaverine inhibition of both [
3 H]piclamilast and [ 3 H]rolipram was adequately described by a one-site model, with K i values in the low micromolar range; similar data were obtained with the nonselective PDE inhibitor 3-isobutyl-1-methylxanthine. Vinpocetine, 9-erythro-(2-hydroxy-3-nonyl)adenine, and zaprinast, at a concentration of 1 mM, inhibited less than 50% of the total specific binding of either radioligand.
Discussion
In the present study, the binding of (Souness et al., 1995 (Souness et al., , 1996 Barnette et al., 1996; Duplantier et al., 1996; Kelly et al., 1996; Souness et al., 1999) . In most of these studies, inhibition of [ 3 H]rolipram binding is used to evaluate affinity for the HARBS, while inhibition of PDE4 hydrolytic activity in a cell-free system is used to evaluate affinity for the LARBS. The LARBS is difficult to study using [ 3 H]rolipram binding. Jacobitz and colleagues (1996) used an equilibrium filtration technique to detect both low-and high-affinity rolipram binding; by using this method, the filter washing protocol is eliminated. Because the ligand/receptor complex is not diluted during the separation procedure, the equilibrium condition is maintained and the ligand bound to the low-affinity site does not dissociate. However, as a consequence, nonspecific binding in this assay is highly variable. Equilibrium dialysis is another method used to study the LARBS (Rocque et al., 1997) . A true equilibrium binding constant can be jpet.aspetjournals.org Downloaded from measured by using this method. However, a high protein concentration is required to obtain an adequate signal-tonoise ratio.
Recombinant systems that express either high-or lowaffinity conformations of PDE4 have been developed to evaluate inhibitors (Bardelle et al., 1999; Allen et al., 1999) . PDE4A330, a PDE4A truncate, expressed in Chinese hamster ovary cells exhibits only the low-affinity conformation, while PDE4A4, 4B2, 4C2, and 4D3 all adopt a high-affinity binding conformation for rolipram. These systems can be used to screen and optimize inhibitors against the low-affinity conformation of PDE4.
Piclamilast is a selective and very potent PDE4 inhibitor (Karlsson et al., 1993; Ashton et al., 1994) . In contrast to rolipram, piclamilast binds with high affinity to both the HARBS and the LARBS (Souness et al., 1995 3 H]rolipram binding was better described by a two-component model; its dissociation, however, was adequately described by a one-site model. Previously, Schneider and coworkers (1986) reported that both the association and dissociation of rolipram binding are biphasic.
At the active site of PDE4 there are two divalent metal ions in a binuclear motif that are involved in both cAMP binding and catalysis (Laliberte et al., 2000; Xu et al., 2000) . [
3 H]rolipram binding is Mg 2ϩ -dependent (Schneider et al., 1986) . It has been suggested that the HARBS and the LARBS are the consequence of PDE4 binding to its metal cofactor, such as Mg 2ϩ (Laliberte et al., 2000) . Mg 2ϩ , Mn 2ϩ , and Co 2ϩ all stabilize high-affinity rolipram binding to the PDE4 holoenzyme. In the absence of the divalent cations, only low-affinity rolipram binding to the apoenzyme is detected (Liu et al., 2001) . Furthermore, in vitro, protein kinase A phosphorylation of PDE4A4, which shifts the potencies of (R)/(S)-rolipram toward their holoenzyme binding affinities, activates the enzyme by increasing its sensitivity to the Mg 2ϩ cofactor. Piclamilast exhibits equal affinity for the HARBS and the LARBS. However, in the present study, piclamilast binding to PDE4 was increased in the presence of Mg 2ϩ . Huang and coworkers (2000) also found that piclamilast binds preferentially to the holoenzyme. This suggests that Mg 2ϩ dependence of inhibitor binding does not fully predict the nature of inhibitor interaction with the HARBS and the LARBS.
[ Souness and coworkers (1992) reported that the binding of rolipram, but not piclamilast, to eosinophils is altered by solubilization or treatment with vanadate/glutathione. These results suggest that the affinity of rolipram binding, but not that of piclamilast, is sensitive to the conformational state of PDE4. The difference in K d values for [ 3 H]rolipram binding to membrane and cytosolic fractions may be due in part to the differential expression pattern of PDE4 variants. For example, PDE4A1 is expressed solely in membrane fractions, while PDE4A5 is present in both membrane and cytosolic fractions (McPhee et al., 1995; Huston et al., 1996; Pooley et al., 1997) . Slight differences in affinity for the differentially distributed variants could translate into a difference in K d values. In addition, association of PDE4 with 3 H]piclamilast binding to membranes prepared from rat cerebral cortex, skeletal muscle, liver, and heart. Membranes were incubated with 2 nM [ 3 H]piclamilast and various concentrations of rolipram at 30°C for 1 h. Data shown are from one of three experiments. The competition curve obtained using cerebral cortical membranes was better described by a two-site model, while the competition curves using the membranes prepared from peripheral tissues were adequately described by a one-site model. K i values are shown in Table 2 . (Draper and Smith, 1966; O'Donnell et al., 1984) .
* Significantly different from corresponding value obtained using membrane preparations, p Ͻ 0.05.
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jpet.aspetjournals.org membrane-associated proteins such as receptor for activated c-kinase (RACK) might result in a different rolipram affinity for membrane and cytosolic preparations containing PDE4 (Yarwood et al., 1999) . All the brain regions tested exhibited the HARBS, with the percentage varying from 47 to 66%. By contrast, the HARBS was not detected in peripheral tissues. The HARBS in rat brain was first demonstrated by Schneider and coworkers (1986) . They reported that the peripheral organs tested showed either no detectable [ 3 H]rolipram binding or a very low specific binding capacity. Although the nature of the HARBS is not yet clear, it has been suggested to be one of the two distinct conformations of PDE4 (Torphy et al., 1992; Souness and Scott, 1993 ICI 63, 197 , and Ro 20-1724 were better described by a two-site model, while the competition curves for piclamilast, cilomilast, roflumilast, and CDP 840 were adequately described by a one-site model. K i values are shown in Table 3 . autoradiographic study using [ 3 H]rolipram binding revealed high binding densities for the HARBS in the cerebellum, olfactory bulb, frontal cortex, subiculum, and the CA1 region of the hippocampus (Kaulen et al., 1989) .
For [ 3 H]piclamilast binding, the competition curves for rolipram, desmethylpiclamilast, ICI 63,197, and Ro 20-1724 were better described by a two-site model, while the competition curves for piclamilast, cilomilast, roflumilast, and CDP 840 were adequately described by a one-site model. For those inhibitors that bound differentially to two states, there was approximately 100-fold greater affinity for the HARBS compared with the LARBS. K i1 values, which represent binding to the HARBS, exhibited more variability compared with K i2 values, which represent binding to the LARBS. The competition curve for piclamilast was adequately described by a one-site model. This is consistent with the finding from saturation analyses that piclamilast binds to both sites with equal affinity. The potency order of PDE4 inhibitors tested in this study was in agreement with the potency orders of these inhibitors reported previously for inhibition of enzyme activity (Schneider et al., 1986; Souness et al., 1997 Souness et al., , 1999 Saldou et al., 1998 3 H]rolipram binding by non-PDE4 inhibitors was less potent and showed no significant differences between the two radioligands. Consistent with their low binding affinities, these drugs also have been shown to be very poor inhibitors of PDE4 enzymatic activity (Schneider et al., 1986; Souness and Scott, 1993; Makhay et al., 2001) .
The LARBS can be studied directly using 3 H]piclamilast a useful tool to study the interaction of PDE4 inhibitors with the LARBS to assess the relationship between inhibitor interactions with this site and their pharmacological effects. Table 3 . 
